AbbVie's Rinvoq conquers Regeneron and Sanofi's Dupixent in eczema trial—again
Fierce Pharma
APRIL 26, 2024
For the second time in four years, AbbVie’s Rinvoq (upadacitinib) has shown superior efficacy to Regeneron and Sanofi’s powerhouse Dupixent (dupilumab) in a head-to-head study in patients with atop | For the second time in four years, AbbVie’s Rinvoq (upadacitinib) has shown better skin clearance than Regeneron and Sanofi’s powerhouse Dupixent (dupilumab) (..)
130 
Let's personalize your content